Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30

$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2024 it was 100.0%.

Period	Period end	Value	Change (pts)
FY2024	Dec 31, 2024	100.0%	–

Change is against the same quarter a year earlier.

Periods

Period	Period end	Value	Change (pts)
Q2 FY2025CQ2 2025	Jun 30, 2025	81.7%	–
Q1 FY2025CQ1 2025	Mar 31, 2025	87.9%	–

Parsed from the XBRL in Adaptimmune Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADAPY.

Revenue growth-54.0% · median 47.8%

Gross margin273.4% · median 53.2%

Operating margin-252.3% · median -212.3%

Net margin-260.8% · median -219.9%

Advertisement
300 × 250

See a number that looks wrong?